Synovial Sarcoma of the Gastrointestinal Tract. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc Ortiz Requena, D., Longacre, T. A., Rosenberg, A. E., Velez Torres, J. M., Yanchenko, N., Garcia-Buitrago, M. T., Voltaggio, L., Montgomery, E. A. 2023: 100383


We report the clinicopathologic and immunohistochemical features of 18 cases of confirmed primary synovial sarcoma of the gastrointestinal tract. The neoplasms arose in 10 women and 8 men ranging in age from 23 to 81 years (mean: 50; median: 57.5 years). The tumors for which size was known ranged from 1.8 to 15.0 cm (mean: 5.2; median: 5.1 cm). Microscopically, fourteen synovial sarcomas were of the monophasic type, two were biphasic, and two were poorly differentiated. Immunohistochemical analysis of four cases showed strong, diffuse staining for SS18::SSX (4/4 cases). Pancytokeratin and EMA immunohistochemistry were performed on 13 and 9 tumors, respectively, and each showed patchy-to-diffuse staining. By RT-PCR, 3 cases were positive for the SS18::SSX1 and 2 cases were positive for the SS18::SSX2 gene fusion. Six cases contained an SS18 gene rearrangement by fluorescence in-situ hybridization, and NGS identified a SS18::SSX2 gene fusion in one case. Clinical follow-up information was available for 9 patients (4 months to 4.6 years; mean, 2.8 y; median: 29 months), and one patient had a recent diagnosis. Three patients died of disease within 41 to 72 months (mean, 56 months) of their diagnosis. Five patients were alive without evidence of disease 4 to 52 months (mean, 17.6 months) after surgery; of which one of these patients received additional chemotherapy treatment after surgery due to recurrence of the disease. A single patient was alive with intraabdominal recurrence 13 months after surgery. We conclude that synovial sarcoma of the gastrointestinal tract is an aggressive tumor, similar to its soft tissue counterpart, with adverse patient outcomes. It is important to distinguish it from morphologically similar gastrointestinal tract lesions that may have different treatment regimens and prognoses.

View details for DOI 10.1016/j.modpat.2023.100383

View details for PubMedID 37972927